In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.24 a new company low.

Within Biotechnology & Pharmaceuticals industry BioStem Technologies, Inc. booked the highest Quick Ratio than Biostem Technologies in the second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from to 3337.

Explain Quick Ratio?
How much Cash & cash equivalents BSEM�s has?
What are BSEM�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BSEM/financial-strength

https://api.csimarket.com/api/v1/companies/BSEM/fundamentals

https://api.csimarket.com/api/v1/companies/BSEM/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BSEM Quick Ratio	(Jun 30 2026) Q2	(Dec 31 2025) Q2
Y / Y Current Liabilities Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.24	Subscribe	Subscribe	Subscribe	Subscribe
BSEM's Total Ranking	# 3337	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	139.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-76.44 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 0
Healthcare Sector	# 0
Overall Market	# 0

Quick Ratio Statistics
High	Average	Low
2.48	1.36	0.24
(Dec 31 2025)		(Jun 30 2026)

Financial Statements
Biostem Technologies's Current Liabilities	$ 29 Millions	Visit BSEM's Balance sheet
Biostem Technologies's Cash & cash equivalent	$ 7 Millions	Visit BSEM's Balance sheet
Source of BSEM's Sales		Visit BSEM's Sales by Geography

Cumulative Biostem Technologies's Quick Ratio

BSEM's Quick Ratio for the trailling 12 Months

BSEM Quick Ratio	(Jun 30 2026) 12 Months	(Dec 31 2025) 12 Months	12 Months	12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.9	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3337	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	239.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	23.56 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BSEM Financial Strength Comparisons >> Go to Compare BSEM Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $28.50 millions, cumulative Quick Ratio decreased to 0.9 below the Biostem Technologies, Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry BSEM achieved the highest Quick Ratio. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents BSEM�s has?
What are BSEM�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 0
Healthcare Sector	# 0
Within the Market	# 3337

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.48	1.36	0.24
(Dec 31 2025)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Halozyme Therapeutics Inc	0.61	$ 231.081 Millions	$ 375.965 Millions
Dbv Technologies S a	0.60	$ 23.900 Millions	$ 40.000 Millions
Silexion Therapeutics Corp	0.57	$ 2.258 Millions	$ 3.976 Millions
Atlantic Coastal Acquisition Corp Ii	0.52	$ 4.291 Millions	$ 8.225 Millions
Surrozen Inc	0.50	$ 102.039 Millions	$ 203.292 Millions
Pluri Inc	0.40	$ 13.126 Millions	$ 32.719 Millions
Outlook Therapeutics Inc	0.39	$ 11.242 Millions	$ 28.679 Millions
Neurocrine Biosciences Inc	0.37	$ 390.500 Millions	$ 1,046.100 Millions
Curis Inc	0.37	$ 5.100 Millions	$ 13.675 Millions
Creative Medical Technology Holdings Inc	0.36	$ 0.250 Millions	$ 0.699 Millions
Xtant Medical Holdings Inc	0.33	$ 9.870 Millions	$ 29.963 Millions
BioStem Technologies, Inc.	0.24	$ 6.962 Millions	$ 28.504 Millions
Champions Oncology Inc	0.23	$ 4.358 Millions	$ 18.729 Millions
ADAPTIN BIO, INC.	0.22	$ 0.670 Millions	$ 3.036 Millions
Biogen Inc	0.15	$ 569.400 Millions	$ 3,917.100 Millions
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions
Bioatla Inc	0.06	$ 1.544 Millions	$ 23.951 Millions
Viskase Holdings inc	0.06	$ 7.911 Millions	$ 123.630 Millions
Biomx Inc	0.06	$ 0.585 Millions	$ 10.180 Millions
Tevogen Bio Holdings Inc	0.06	$ 1.082 Millions	$ 19.573 Millions

Date modified: 2026-10-24T05:30:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.